COMMUNIQUÉS West-GlobeNewswire

DARZALEX® (daratumumab) subcutaneous (SC) formulation-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned

27/09/2024 - 19:05

Study demonstrates a minimal residual disease (MRD)-negativity rate of 60.9 percent and 43 percent reduction in the risk of progression or death 1 Phase 3 CEPHEUS study results presented in late-breaking oral [...]

Communities Across the Commonwealth Come Together to Celebrate Massachusetts Good Neighbor Day of Action

27/09/2024 - 18:15

-- A broad range of inspiring events including a “Find Your People” fair, intergenerational dinners, a town scavenger hunt, free YMCA admission, and others help people and communities connect-- BOSTON, Sept. 27, 2024 ( [...]

Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions

27/09/2024 - 17:00

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from SEQUOIA-HCM ( S afety, E fficacy, and Q uantitative U nderstanding of O [...]

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

27/09/2024 - 15:35

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent approvals in the EU and [...]

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

27/09/2024 - 15:35

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype [...]

Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO

27/09/2024 - 15:35

Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO Dupixent est indiqué à environ 300 000 adultes aux États-Unis présentant une BPCO inadéquatement contrôlée et un [...]

Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray

27/09/2024 - 15:01

Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with strategic contract manufacturer and expanding [...]

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

27/09/2024 - 15:00

28-week data show ESK-001 was generally well tolerated and most patients treated with the top dose of 40 mg twice daily achieved PASI 75 Three additional data presentations further support ESK-001’s potential to offer a [...]

Turning Point of Tampa Now In-Network with Blue Cross Blue Shield Insurance

27/09/2024 - 15:00

TAMPA, FL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Turning Point of Tampa, a top-rated addiction treatment facility since 1987, is proud to announce that it is now in-network with Blue Cross Blue Shield, effective September [...]

Burning Rock Announces Changes to Management and Board of Directors

27/09/2024 - 14:37

GUANGZHOU, China, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) (the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in [...]

Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering

27/09/2024 - 14:30

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company with two FDA-approved products and a late-stage asset in development for the [...]

Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission

27/09/2024 - 14:30

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]

Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

27/09/2024 - 14:30

Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film Outlines the development strategy for the Company’s [...]

TALVEY®▼ (talquetamab) and DARZALEX® (daratumumab) subcutaneous (SC) formulation-based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma

27/09/2024 - 14:21

Updated data show 100 percent overall response rate, with 56 percent of patients achieving complete response or better with weekly dosing , s upporting the combinability of the GPRC5 D bispecific antibody 1 Safety [...]

Novel combination of TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) suggest high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease

27/09/2024 - 14:21

Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to talquetamab and teclistamab monotherapies 1 BEERSE, BELGIUM, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag [...]

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

27/09/2024 - 14:00

Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population Study design intended to enable supplemental [...]

AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment

27/09/2024 - 14:00

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ET OCALA, Fla., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or [...]

33 Medical Wins 2024 Best Technology in Spine Award for Innovative NuvoDisc® Device

27/09/2024 - 14:00

Boca Raton, FL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- 33 Medical, Inc., a leader in cutting-edge spinal health innovations, is proud to announce that its NuvoDisc ® medical device has been awarded the prestigious 2024 Best [...]

WeightWatchers Announces Executive Leadership Transition

27/09/2024 - 14:00

Independent Board Member Tara Comonte Will Serve as Interim Chief Executive Officer Sima Sistani Will Step Down as CEO and Director NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“ [...]